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The transcription factor hypoxia inducible factor
(HIF)-1 is a key regulator of the cellular response to
hypoxia. HIF-1 consists of a constitutively expressed
HIF-1b subunit and an inducible HIF-1a subunit [1–
4]. The main mechanism responsible for stabilization
of HIF-1a is the inhibition of prolyl 4-hydroxylase
domain (PHD) proteins, which hydroxylate the HIF-1a
subunit in the presence of oxygen, leading to its sub-
sequent ubiquitination and degradation [5]. Growth
factors, in particular when their expression is driven by
oncogenes, iron chelators and reactive oxygen species,
are also reported to increase HIF-1a transcription
Keywords
Akt; endothelial cells; HIF; hypoxia; nitric
oxide
Correspondence
O. Feron, Unit of Pharmacology and
Therapeutics, UCL-FATH5349, 52 Avenue
E. Mounier, B-1200 Brussels, Belgium
Fax: +32 2 764 5269
Tel: +32 2 764 5264
E-mail: olivier.feron@uclouvain.be
Present address
Radiotherapy Department, University of
Lie`ge, Belgium
*These authors contributed equally to this
work
(Received 12 September 2008, revised 7
November 2008, accepted 13 November
2008)
doi:10.1111/j.1742-4658.2008.06798.x
Heterogeneities in tumor blood ﬂow are associated with cyclic changes in
pO2 or cyclic hypoxia. A major difference from O2 diffusion-limited or
chronic hypoxia is that the tumor vasculature itself may be directly inﬂu-
enced by the ﬂuctuating hypoxic environment, and the reoxygenation
phases complicate the usual hypoxia-induced phenotypic pattern. Here, we
determined the cyclic hypoxia-driven pathways that modulate hypoxia
inducible factor (HIF)-1a abundance in endothelial cells to identify possible
therapeutic targets. We found that exposure of endothelial cells to cycles of
hypoxia ⁄ reoxygenation led to accumulation of HIF-1a during the hypoxic
periods and the phosphorylation of protein kinase B (Akt), extracellular
regulated kinase (ERK) and endothelial nitric oxide synthase (eNOS) dur-
ing the reoxygenation phases. We identiﬁed stimulation of mitochondrial
respiration and activation of the phosphoinositide-3 kinase (PI3K) ⁄Akt
pathway during intervening reoxygenation periods as major triggers of the
stabilization of HIF-1a. We also found that the NOS inhibitor nitro-l-argi-
nine methyl ester further stimulated the cyclic hypoxia-driven HIF-1a accu-
mulation and the associated gain in endothelial cell survival, thereby
mirroring the effects of a PI3K ⁄Akt inhibitor. However, combination of
both drugs resulted in a net reduction in HIF-1a and a dramatic in
decrease in endothelial cell survival. In conclusion, this study identiﬁed
cyclic hypoxia, as reported in many tumor types, as a unique biological
challenge for endothelial cells that promotes their survival in a HIF-1a-
dependent manner through phenotypic alterations occurring during the
reoxygenation periods. These observations also indicate the potential of
combining Akt-targeting drugs with anti-angiogenic drugs, in particular
those interfering with the NO pathway.
Abbreviations
Akt, protein kinase B; CyH, cyclic hypoxia; ERK, extracellular regulated kinase; eNOS, endothelial nitric oxide synthase; H3, third period of
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and ⁄or its stabilization [6]. Conversely, inhibitors of
mitochondrial respiration, including nitric oxide, may
prevent the stabilization of HIF-1a during hypoxia [7].
However, the impact of nitric oxide on HIF-1a is not
easy to assess, as NO has been shown to stabilize
HIF-1a at O2 concentrations above those usually con-
sidered hypoxic and even in ambient air [8–10].
The HIF-1a-dependent cellular response also
appears to depend on the nature of the cells. Vascu-
lar endothelial cells were recently documented to
induce HIF-1a at lower O2 concentrations than
smooth muscle cells, ﬁbroblasts or tumor cells [11].
At a ﬁrst glance, the concept of hypoxic endothelial
cells may appear biologically irrelevant considering
the unique location of the endothelium at the inter-
face with O2-transporting cells in the blood. However,
intermittent blood ﬂow and cyclic hypoxia in tumors
[12–23] are examples of conditions where endothelial
cells are exposed to very low levels of O2. We
recently reported that cyclic hypoxia (i.e. several
cycles of hypoxia ⁄ reoxygenation) promoted the sur-
vival of endothelial cells through an HIF-1a-depen-
dent mechanism [24]. However, key questions
remained unaddressed in that study. For instance,
does the accumulation of HIF-1a during cyclic
hypoxia result from the lack of degradation during
the reoxygenation phases, or are some signaling cas-
cades activated during the reoxygenation phase that
may inﬂuence the expression of HIF-1a during
hypoxia? This is of crucial importance as dissection
of these mechanisms may lead to new therapeutic
strategies to sensitize endothelial cells to anti-angio-
genic and conventional anti-tumor treatments.
In this study, we therefore exposed endothelial cells
to cyclic hypoxia (CyH), and examined the impact of
cycles of hypoxia ⁄ reoxygenation on the extent of acti-
vation of known regulators of HIF-1a, namely phos-
phoinositide-3 kinase (PI3K) ⁄protein kinase B (Akt),
extracellular regulated kinase (ERK) and endothelial
nitric oxide synthase (eNOS). This allowed us to iden-
tify the critical role of reoxygenation periods on the
Akt pathway and mitochondrial activity, which both
participate in HIF-1a stabilization. Incidentally, this
study indicated that PI3K ⁄Akt and eNOS activation
have opposite effects on HIF-1a during cyclic
hypoxia; caution is therefore required in the use of
NOS inhibitors as single anti-tumor treatments. More
generally, by providing new insights into the regula-
tion of HIF-1a in the context of tumor O2 ﬂuctua-
tions, this study integrates the apparently paradoxical
modes of regulation of HIF-1a by hypoxia and
oxidative stress.
Results
HIF-1a accumulates in response to cyclic hypoxia
despite degradation during reoxygenation
We examined the impact of three cycles of 1 h hypox-
ia ⁄ 30 min reoxygenation (versus 1, 2 and 3 h of con-
tinuous hypoxia) on the abundance of HIF-1a. This
protocol of cyclic hypoxia (1 h hypoxia ⁄ 30 min reoxy-
genation) was based on previous measurements of
ﬂuctutations in the tumor vasculature occurring at the
frequency of 0.5–1 cycle per hour [19,25,26]. We found
that both continuous and cyclic hypoxia (CyH)
induced HIF-1a accumulation (Fig. 1A,B). Interest-
ingly, HIF-1a progressively accumulated at each new
hypoxic cycle during the CyH protocol (i.e. H1, H2
and H3), despite degradation during the intervening
reoxygenation steps (i.e. R1, R2 and R3). As shown in
Fig. 1C, the level of HIF-1a was signiﬁcantly higher
after three 1 h periods of hypoxia than after three
continuous hours of hypoxia. An increase in HIF-1a
stabilization (versus transcription) was conﬁrmed by
the failure of actinomycin D to block HIF-1a accumu-
lation during the CyH protocol (data not shown). To
conﬁrm the functional relevance of the observed HIF-1
a stabilization, expression of the endothelial hypoxia-
responsive element-regulated gene COX-2 was ex-
amined. Figure 1D shows that COX-2 expression was
7.2-fold increased after CyH, but continuous hypoxia
only led to a threefold increase (versus normoxic con-
ditions). The HIF dependency of the COX-2 induction
was shown using echinomycin, a pharmacological
hypoxia-responsive element-interfering drug [27], which
completely prevented the increase in COX-2 transcript
abundance (data not shown).
Cyclic hypoxia activates a variety of signaling
cascades during the reoxygenation periods
We evaluated the activation of known regulators of
HIF-1a activity ⁄ expression, namely Akt, ERK and
eNOS [28,29], under continuous (Fig. 2A) and cyclic
(Fig. 2B) hypoxia conditions. We found that activation
of Akt and ERK, as determined by the extent of phos-
phorylation of these proteins, presented an opposite
pattern to that of HIF-1a. Phospho-Akt and phospho-
ERK signals were increased during reoxygenation,
either after the 3 h continuous hypoxia (Fig. 2A) or
during the periods of reoxygenation after each hypoxic
cycle (Fig. 2B,C). Figure 2 also shows that phosphory-
lation of eNOS on serine 1177, a hallmark of eNOS
activation, was similarly inﬂuenced by reoxygenation,
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but to a slightly lower extent (see Fig. 2C for quantiﬁ-
cation).
The PI3K/Akt and eNOS pathways oppositely
modulate the CyH-driven induction of HIF-1a
To determine the potential inﬂuence of the
hypoxia ⁄ reoxygenation-dependent activation of Akt,
ERK and eNOS on HIF-1a upregulation, we used
pharmacological inhibitors of each speciﬁc pathway.
Figure 3A shows that LY294002, an inhibitor of the
activity of PI3K (a kinase known to act upstream of
Akt), completely prevented activation of Akt and pre-
cluded the accumulation of HIF-1a throughout cyclic
hypoxia (see Fig. 3D for quantiﬁcation). By contrast,
PD98059, which reduced the extent of ERK phosphor-
ylation to approximately 20% of the control signal
during reoxygenation, failed to prevent progressive
accumulation of HIF-1a during the hypoxic periods
(Fig. 3B). Note that the HIF-1a signal detected after
the third hypoxic period (i.e. H3) and the phospho-sig-
nal detected after the third reoxygenation period (i.e.
R3) in the absence of treatments are shown on the
immunoblots as internal standards.
In contrast to the two other inhibitors, the NOS
inhibitor nitro-l-arginine methyl ester (l-NAME) stim-
ulated HIF-1a accumulation to higher levels than the
maximal signal in the absence of l-NAME (i.e. at H3)
(see Fig. 3C,D for quantiﬁcation).
Cyclic hypoxia stimulates the O2
consumption rate
As NO has previously been reported to inhibit mito-
chondrial O2 consumption [11], the l-NAME-stimu-
































































































Fig. 1. HIF-1a accumulates in response to cyclic hypoxia despite
degradation during the reoxygenation periods. (A, B) Representative
HIF-1a immunoblots from endothelial cells collected at various time
points during the continuous and cyclic hypoxia protocols. (A) Endo-
thelial cells were exposed to hypoxia (< 1% O2) for the indicated
time periods, i.e. 1, 2 or 3 continuous hours (H0-1, H0-2 and H0-3,
respectively); after the 3-h hypoxia, cells were reoxygenated (R) for
30 min. (B) Endothelial cells were exposed to three cycles of 1 h
hypoxia (H1, H2 and H3) interrupted (or followed) by 30 min reoxy-
genation (R1, R2 and R3). For both (A) and (B), b-actin expression
is shown as a gel loading control. These experiments were
repeated three times with similar results. (C, D) Influence of
normoxia, 3 h continuous hypoxia and cyclic hypoxia (CyH; 3 · 1 h)
on (C) HIF-1a protein accumulation (at H3) and (D) COX-2
mRNA expression (at R3) in endothelial cells (**P < 0.01 versus
normoxia; §P < 0.05 and §§P < 0.01 versus 3 h continuous hypoxia,
n = 5–8).
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changes in cell respiration could be involved in the
modulation of HIF-1a abundance observed through-
out cyclic hypoxia. We ﬁrst evaluated the O2 consump-
tion rate in endothelial cells exposed to the CyH
protocol described above. We found that the CyH pre-
challenge signiﬁcantly stimulated the respiratory
metabolism of endothelial cells (P < 0.01, n = 5)
versus cells exposed to 3 h continuous hypoxia or
maintained in normoxia (Fig. 4A). This metabolic
adaptation was progressive, with the O2 consumption
rate increasing after each new hypoxia ⁄ reoxygenation
cycle (see Fig. 4B).
We then used rotenone, an inhibitor of mitochon-
drial chain respiration, and found that it could prevent
HIF-1a accumulation following three cycles of 1 h
hypoxia (Fig. 4C). Addition of rotenone had no effect
on the induction of HIF-1a after uninterrupted 1 or 3
h hypoxia, indicating that, under our experimental
conditions, acceleration of respiration was a major
trigger of HIF-1a stabilization in response to CyH.
Furthermore, when we used of combined treatment
with l-NAME with rotenone, the NOS inhibitor failed
to induce accumulation of HIF-1a (Fig. 4D), conﬁrm-
ing that, in our CyH protocol, the l-NAME-mediated
increase in HIF-1a (see Fig. 3C,D) very probably
resulted from NO-dependent inhibition of the respira-
tory chain.
PI3K ⁄Akt and eNOS inhibitors exert opposite
effects on cyclic hypoxia-driven cell survival
We then sought to determine whether the PI3K inhibi-
tor LY294002 could prevent l-NAME-driven ampliﬁ-
cation of the HIF-1a response in endothelial cells and
how the combination of both inhibitors could inﬂuence
the fate of cells exposed to CyH. Figure 5A shows that
the l-NAME-driven increased abundance of HIF-1a
was largely prevented by co-administration of
LY294002 (see Fig. 5B for quantitative analysis). We
next used a clonogenic assay to evaluate the effects of
both inhibitors. We observed a dramatic gain in endo-
thelia cell survival when ﬁrst pre-challenged by cyclic
hypoxia (versus cells maintained in normoxia, which
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Fig. 2. Post-hypoxic reoxygenation stimulates Akt, ERK and eNOS
phosphorylation. Representative immunoblots for the detection of
phospho-Akt (Ser473), phospho-ERK (Thr185 ⁄ Tyr187) and phospho-
eNOS (Ser1177) in endothelial cells exposed to the continuous (A)
and cyclic (B) hypoxia protocols described in the legend to Fig. 1.
Immunoblots for total Akt, ERK and eNOS are also shown and
were used for signal normalization. These experiments were
repeated two or three times with similar results. (C) Extent of Akt,
ERK and eNOS phosphorylation measured after the third period of
reoxygenation (R3). Data are presented as fold induction versus H3
conditions (third period of hypoxia): **P < 0.01,*P < 0.05 (n = 3–4).
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estingly, while LY294002 dose-dependently inhibited
the CyH-driven protection of endothelial cells, the
NOS inhibitor l-NAME signiﬁcantly increased the
survival advantages conferred by CyH (Fig. 5C), in
agreement with the net increase in the HIF-1a immu-
noblot signal (Fig. 5A,B). Importantly, when we com-
bined the PI3K and NOS inhibitors, we found that the
reduction in endothelial cell survival was similar to
that obtained with LY294002 alone, suggesting that
the pro-survival effects of l-NAME could be elimi-
nated by use of LY294002 (Fig. 5C).
Discussion
The major ﬁndings of this study are that (a) cyclic
hypoxia, an increasingly recognized hallmark of many
tumor types [23], leads to a unique activation pattern
of key signaling enzymes including Akt and eNOS,
which tune the accumulation of HIF-1a in endothelial
cells, (b) the PI3K ⁄Akt activation occurring during the
reoxygenation phases accounts for the observed CyH-
driven HIF-1a stabilization, a phenomenon further
exacerbated by the increase in O2 consumption in
CyH-exposed endothelial cells, (c) the eNOS activation
(also triggered by CyH) partly attenuates the HIF-1a
increase by interfering with cell respiration, and (d) the
HIF-1a-driven increase in the survival of endothelial
cells exposed to CyH is further increased by a NOS
inhibitor but may be combated by (co-) administration
of a PI3K ⁄Akt inhibitor.
The origins of cyclic exposure of cells within tumors
to various pO2 levels are multiple as described above.
Here we focused on the effects of CyH on endothelial
cells, a cell type that is not directly concerned by
hypoxia in healthy tissues. The location of the endo-
thelium at the interface between O2-transporting
blood cells and perfused tissues normally protects
them from any major inﬂuence of hypoxia. However,
in tumors, although so-called chronic hypoxia is
dependent on the diffusion of O2 and therefore does
not inﬂuence endothelial cells located at the begin-
ning of the O2 gradient, heterogeneities in tumor
blood ﬂow directly inﬂuence the endothelium of
tumor vessels.
Here, we provide mechanistic insights that account
for the accumulation of HIF-1a in endothelial cells
exposed to CyH. Cyclic ﬂuctuations of pO2 lead to a
unique combination of parameters with direct and
indirect impacts on HIF-1a accumulation. First, the
reoxygenation phases are associated with activation of
signaling enzymes, including Akt, ERK and eNOS.
Using pharmacological inhibitors, we identiﬁed the key
role for the reoxygenation-driven PI3K ⁄Akt pathway
in stabilization of HIF-1a during consecutive hypoxic
periods. The prevention of HIF-1a accumulation in
the presence of a PI3K ⁄Akt inhibitor (as observed in























































Fig. 3. CyH-driven activations of Akt, ERK and eNOS influence
HIF-1a accumulation differently. (A–C) Representative HIF-1a immu-
noblots from endothelial cells exposed to the cyclic hypoxia proto-
col (described in the legend to Fig. 1) and pre-treated with the
following pharmacological inhibitors: (A) 15 lM LY294002, (B)
10 lM PD98059 or (C) 5 mM L-NAME. The effects of LY294002 (A)
and PD98059 (B) treatments on the extent of Akt and ERK phos-
phorylation, respectively, are also shown for validation of the inhibi-
tion of the corresponding phosphorylations (L-NAME is not an
eNOS phosphorylation inhibitor). Immunoblots for total Akt and
ERK are also presented and were used as controls of gel loading.
These experiments were repeated twice with similar results. (D)
Impact of the indicated pharmacological inhibitors on the relative
HIF-1a abundance measured after the third period of hypoxia (H3):
**P < 0.01, n.s., not significant (n = 3–4).
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Fig. 3A) was previously reported to involve a reduc-
tion in steady-state concentrations of Hsp90 and ⁄or
Hsp70 [30]. Interestingly, the phosphorylation of Akt
observed during the reoxygenation phases did not
increase proportionally to the accumulation of HIF-1a
(see Figs 1B and 2B). Together, these data indicate
that Akt activation is necessary but not sufﬁcient to
support the CyH-triggered accumulation of HIF-1a.
This led us to identify the acceleration of the endothe-
lial cell respiration as a secondary mechanism driven
by cyclic hypoxia and promoting HIF-1a accumula-
tion. The decrease in intracellular O2 bioavailability
parallels the progressive accumulation of HIF-1a at
each new hypoxic cycle (see Figs 1B and 4B). These
data indicate that CyH-induced stimulation of the
mitochondrial respiratory chain (i.e. the increase in O2
consumption) and the concomitant activation of Akt
concur to support the accumulation of HIF-1a during
CyH.
Of note, in the immunoblotting data corresponding
to the various hypoxic and reoxygenation phases, cells
were collected at the end of the 60 min hypoxia or
30 min reoxygenation periods, respectively. This may
have led an underestimation of the ability of CyH to
both favor phosphorylation of signaling enzymes such
as Akt during hypoxia and support induction of
HIF-1a during at least part of the reoxygenation
period. Alterations in cell respiration (as reported in
Fig. 4A) and thus cell metabolism could also account
for a reduction in the extent of Akt, ERK and eNOS
phosphorylation during the hypoxia periods. However,
given the long-term ﬂuctuations of pO2 values reported
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Fig. 4. CyH increases the oxygen consumption rate in endothelial cells. (A) Endothelial cell oxygen consumption measured by electron para-
magnetic resonance at baseline (open square; n = 5) as well as after 3 h continuous hypoxia (closed triangle, n = 5) and cyclic (3 · 1 h)
hypoxia (closed square, n = 4), as described in the legend to Fig. 1; note that the measurements were performed after 30 min reoxygen-
ation at the end of both protocols. (B) Slope values derived from the corresponding O2 consumption rate (lMÆmin
)1) as observed in Fig. 4A
(left y axis) and the corresponding HIF-1a expression values (right y axis) determined as in Fig. 1; note the parallel increases in the slope
values and HIF-1a accumulation with the number of hypoxia ⁄ reoxygenation cycles. (C) Relative abundance of HIF-1a after the third period of
hypoxia (i.e. H3) in endothelial cells exposed or not to 2 lM rotenone; these experiments were repeated three times with similar results.
**P < 0.01 versus control conditions (D) Representative HIF-1a immunoblots from endothelial cells exposed to cyclic hypoxia after pre-
treatment with 5 mM L-NAME and 2 lM rotenone; the immunoblot signal at H3 in the absence of pharmacological treatment is shown as a
control. This experiment was repeated twice with similar results.
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to occur in vivo (instead of the three cycles used in our
experimental protocol) and ⁄or a yet higher rate of pO2
alternation as recently reported [18,31], permanent
instabilities in tumor blood ﬂow and oxygenation may
instead favor continuous Akt activation and HIF-1a
expression in tumor endothelial cells.
Our study also showed opposite effects of PI3K ⁄Akt
and eNOS inhibitors on the CyH-driven survival of
endothelial cells (see Fig. 5C), thereby conﬁrming the
differential effects of these drugs on HIF-1a abun-
dance (Fig. 5A,B). In particular, exacerbation of
HIF-1a induction by l-NAME indicates that the stim-
ulatory effect of CyH on HIF-1a was dampened by
eNOS activation ⁄phosphorylation. Furthermore, the
failure of the NOS inhibitor to maintain the induction
of HIF-1a in the presence of rotenone (Fig. 4D)
strongly suggests that NO exerts these effects through
inhibition of the mitochondrial respiratory chain. This
is in agreement with the previously reported redistribu-
tion of oxygen toward prolyl hydroxylases observed
upon inhibition of mitochondrial respiration by NO
under hypoxia [7]. Importantly, co-administration of a
PI3K ⁄Akt inhibitor obliterated the stimulatory effects
of the NOS inhibitor on HIF-1a. Therefore, from a
therapeutic perspective, our study provides a new
rationale for the use of Akt inhibitors to abrogate the
pro-survival effects of CyH, and also provides evidence
that use of NOS inhibitors (in particular for their anti-
angiogenic potential) may beneﬁt from the co-adminis-
tration of Akt-targeting drugs. The interest in such a



























































































































Fig. 5. PI3K ⁄ Akt inhibition and NO blockade oppositely influence
CyH-driven survival of endothelial cells. Endothelial cells were
exposed to cyclic hypoxia (as described in the legend to Fig. 1)
after pre-treatment (or not) with 15 lM LY294002, 5 mM L-NAME or
a combination of both. (A) Representative HIF-1a immunoblots
from endothelial cells collected at the end of the third hypoxic cycle
(H3). (B) Relative HIF-1a abundance after the third period of hypoxia
(i.e. H3) in endothelial cells pre-treated as indicated (*P < 0.05,
**P < 0.01 versus untreated conditions, n = 5–6). (C) Clonogenic
survival of endothelial cells maintained in normoxia (N) or after
exposure to cyclic hypoxia (CyH) in the presence of the indicated
pharmacological treatments. Results are expressed as a percentage
of the survival obtained after CyH (*P < 0.05, **P < 0.01 versus
















Fig. 6. Schematic representation of the interplay between the mul-
tiple factors regulating HIF-1a abundance in endothelial cells
exposed to CyH. The stimulatory effects of CyH on both the
PI3K ⁄ Akt pathway and the cell respiration rate lead to an increase
in HIF-1a stabilization, thereby promoting endothelial cell survival.
These effects are partly attenuated by the concomitant eNOS acti-
vation through probable inhibition of the mitochondrial chain. Con-
sequently, the drugs targeting these enzymes have opposite
effects: a PI3K ⁄ Akt inhibitor will leave the effects of NO unbridled,
promoting a decrease in HIF-1a abundance, whereas a NOS inhibi-
tor will accentuate the induction of HIF-1a in response to CyH.
P. Martinive et al. Cyclic hypoxia and HIF-1a
FEBS Journal 276 (2009) 509–518 ª 2008 The Authors Journal compilation ª 2008 FEBS 515
PI3K ⁄Akt inhibitors to prevent eNOS activation
(through phosphorylation on serine 1177) and the
consequent NO-mediated angiogenesis [32,33].
In conclusion, this study offers new insights into the
impact of cyclic hypoxia on vascular cells, an under-
estimated component of the tumor stroma in terms of
phenotypic alterations by hypoxia. The scheme shown
in Fig. 6 summarizes the interplay between the major
signaling events elicited by cyclic hypoxia in endo-
thelial cells. The accumulation of HIF-1a in response to
cyclic hypoxia is largely promoted by Akt activation
during the periods of higher pO2, favored by a concomi-
tant increase in the oxygenation consumption rate of
endothelial cells and further increased by pharmaco-
logical inhibition of NOS activity. Our study underlines
the therapeutic relevance of combining emerging strate-
gies that block the PI3K ⁄Akt pathway [34] with other
anti-cancer modalities (especially drugs interfering with
the eNOS or COX-2 pro-survival pathways, both of
which are found to be activated in response to cyclic
hypoxia) to take full advantage of a reduction in the




Human umbilical vein endothelial cells were routinely cul-
tured in 60 mm dishes in endothelial cell growth medium
(Clonetics, Walkersville, MD, USA). Two hours before
starting the treatments, cells were serum-starved; for long-
term survival studies, culture medium was re-supplemented
with serum. To achieve and control hypoxia conditions,
cells were placed in a modular incubator chamber (Billups
Rothenberg Inc., Del Mar, CA, USA) and ﬂushed for
10 min with a gas mixture of 5% CO2 ⁄ 95% N2; the ﬁnal
pO2 value measured in the extracellular medium was con-
sistently below 1%. The chamber was then sealed and
placed at 37 C in conventional cell incubator. The cyclic
hypoxia protocol consisted of three periods of 1 h hypoxia
interrupted by 30 min reoxygenation; 1, 2 or 3 h of unin-
terrupted exposure to hypoxia were used for the continu-
ous hypoxia protocol. In some experiments, cells were
treated with rotenone (2 lm), l-NAME (5 mm), LY294002
(15 or 50 lm) or PD98059 (10 lm); all these drugs were
obtained from Sigma (Bornem, Belgium).
Immunoblotting
Endothelial cells were collected and homogenized in a
buffer containing protease and phosphatase inhibitors.
Total lysates were immunoblotted with HIF-1a antibodies
and antibodies directed against phospho- and non-modiﬁed
Akt, eNOS and ERK, as previously described [24,35]. All
the antibodies were purchased from BD Pharmingen (Lex-
ington, KY, USA), except the b-actin antibody that was
used to normalize gel loading, which was obtained from
Sigma.
Real-time PCR
COX-2 mRNA expression was determined after reverse
transcription from total RNA isolated from endothelial
cells exposed or not to hypoxia protocols. Real-time quanti-
tative PCR analyses were performed in triplicate using
SYBR Green PCR Master Mix (Bio-Rad, Nazareth, Bel-
gium) and the primers COX-2 sense (5¢-CAGCCATAC
AGCAAATCCTTG-3¢) and COX-2 antisense (5¢-AATCC
TGTCCGGGTACAATC-3¢). The Ct value (number of
cycles require to generate a ﬂuorescent signal above a pre-
deﬁned threshold) was determined for each sample, and the
relative mRNA expression was calculated using the formula
2DDCt formula after normalization to RPL19 (DCt) and
determination of the difference in Ct (DDCt) between the
various conditions tested.
Clonogenic assay
To assess the effects of cyclic hypoxia on endothelial cell
survival, clonogenic cell survival assays were performed as
previously described [24]. This test (generally reserved for
tumor cells) entails a pro-apoptotic stress for endothelial
cells, which need to recover from an important dilution at
the time of plating. After a 7-day incubation period, cells
were stained with crystal violet and colonies (> 50 cells)
were counted.
O2 consumption assay
Electron paramagnetic resonance oximetry was used to
track the O2 consumption rate in endothelial cells
pre-challenged or not by CyH, according to a method
developed by P. James [36] and further validated by
us [37,38]. A neutral nitroxide, 15N-PDT (4-oxo-2,2,6,
6-tetramethylpiperidine-d16-15N-1-oxyl) (CDN Isotopes,
Quebec, Canada), was added to cells, which were
then drawn into glass capillary tubes. They were then
rapidly placed into quartz electron spin resonance tubes
and maintained at 37 C during recording on a Bruker
EMX electron paramagnetic resonance spectrometer
(Bruker, Brussels, Belgium) operating at 9 GHz.
Statistical analyses
Data are reported as means ± SEM. Student’s t-test and
one- or two-way ANOVA were used where appropriate.
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